DGAP-News: BioCrea GmbH: BioCrea Provides Update on

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 23, 2014 at 2:45 AM

DGAP-News: BioCrea GmbH: BioCrea Provides Update on Development Programs for Partners

DGAP-News: BioCrea GmbH / Key word(s): Research Update BioCrea GmbH: BioCrea Provides Update on Development Programs for Partners 23.04.2014 / 08:30 --------------------------------------------------------------------- Radebeul, Germany, April 23, 2014 - BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today provided an update on two unique proprietary small molecule programs: Long-term acting GABAA positive allosteric modulators (LT GABAA PAMs) to treat epilepsy plus autism; and NMDA receptor 2B (NR2B) negative allosteric modulators (NAMs) to treat depression. The pathways of both therapy approaches have been established in proof-of-concept trials conducted with similar compounds and they both show great potential to overcome limitations of their predecessors. BioCrea has initiated an outlicensing program to expedite the progression of these assets into the clinic. The LT GABAA PAMs program provides innovative compounds for the acute and long-term treatment of a broad-range of seizure disorders. BioCrea's unique PAMs act on a GABAA modulatory site that is different from benzodiazepine or steroid binding sites of currently marketed drugs. The subtype selectivity of these LT GABAA b2-preferring PAMs offers excellent efficacy in multiple seizure disease models combined with a much improved safety profile compared to current treatment approaches. BioCrea's compounds avoid common problems such as cognitive impairment, sedation, tolerance and dependency issues after multiple dosing. The mode of action for this class of compound also opens up the potential to work in combination with existing treatment approaches. BioCrea has developed multiple distinct chemical families with excellent developability profiles, good oral bioavailability, CNS penetration and in vivo activity. By the second half of 2014, BioCrea will have completed the LT GABAA PAM candidate selection. In January 2014 the US Epilepsy Foundation granted its Epilepsy Innovation Seal of Excellence Award to BioCrea for the LT GABAA PAM program. The NR2B NAM program is showing strong potential as a treatment for major depressive disorder (MDD), particularly for treatment resistant patients and patients with suicidal tendencies. By targeting the NMDA receptor subunit NR2B, BioCrea is developing a novel first-in-class program to treat these diseases. NR2B NAM compounds overcome the limited effectiveness, late onset of action and side effects of available antidepressant medications. Clinical studies with predecessor compounds have provided proof-of-concept for this target as a robust, rapid treatment of depression, especially in refractory patients. Studies also show that NR2B subtype-selective antagonists have superior tolerability when compared to non-selective agents like ketamine. BioCrea has addressed the NR2B target through two potent, distinct chemical families with a novel IP position. The compounds are efficacious in in vitro and in vivo assays, have an excellent side effect profile, blood-brain barrier penetration and developability parameters. This includes the potential for oral administration, which has been a difficulty in the development of NR2B selective agents in previous programs. BioCrea's NR2B NAM drug candidate will be ready for IND-enabling studies by year-end. "First-in-class drug discovery based on a clinically validated mechanism of action is our contribution to enhance the probability of success in clinical trials. Both, the LT GABAA PAM and the NR2B NAM approaches have proven pathways through proof-of-concept trials," said Dr. Tom Kronbach, CEO of BioCrea. "We are convinced our compounds with their unique efficacy, side effect profiles and developability parameters have the potential to provide much needed treatment options for refractory patients in a range of debilitating diseases. We are looking to complete our partnering activities to speed up development of these therapies for the benefit of doctors and patients." About BioCrea BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychotic disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). BioCrea was awarded Top Innovator status of the "Top 100" Most Innovative Companies in Germany 2012 by compamedia GmbH. For more information, please visit www.biocrea.com. Contact Dr. Tom Kronbach CEO, BioCrea GmbH Tel.: +49 351 / 4043 3332 Fax: +49 351 / 4043 3216 tom.kronbach@biocrea.com End of Corporate News --------------------------------------------------------------------- 23.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 264091 23.04.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KT&G Launches Heated Tobacco in Kazakhstan's Market

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Paul Taubman Takes Helm at Cold Spring Harbor Lab

Paul Taubman Steers the Ship at CSHL Here's the buzz coming out of Cold Spring Harbor Lab: they're handing the reins over to Paul Taubman. It's like swapping captains in the middle of the ocean—big shoes need to stay afloat. This place isn't just the playground for science nerds; it's a powerhouse in biomedical research. Now, we've got Taubman, a fella who's been...

Expo 2027 Belgrade Volunteer Rush: A Global Draw

Massive Volunteer Interest for Expo 2027 Belgrade Maybe I’m getting soft, but there’s something about the human spirit rallying around big events that gets me, even after seeing my share of market rollercoasters. Expo 2027 in Belgrade is attracting an army of volunteers—over 19,000 folks hankering to lend a hand from 154 different countries. Yeah, you read that...

Segway Powersports Ventures into Baja 1000: Ambitions Run High

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

FSBO.com Boosts Real Estate Game with New Apps

FSBO.com Bets Big on Mobile With New App Launch FSBO.com has unleashed something that might just shake up how we think about buying and selling homes. They're not just rolling out apps—they're weaving another layer onto the fabric of real estate itself. While other players tossed their hats into the app game long ago, FSBO.com is kicking it up a notch with their new iOS...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Bybit Shines at Web Summit 2026 as AI Takes Center Stage

Financial Revolution: Bybit Steals the Spotlight Ever been to a tech show where financial bigwigs mingle with code geeks? Well, that's exactly the scene unfolding at the famed Web Summit 2026, with Bybit throwing down the gauntlet as an official partner. The MEO Arena in Lisbon is buzzing more than a stock ticker on a rollercoaster day, as Bybit flaunts its wares to a...

TalentNeuron and CodeSignal Team Up: Impact on Workforce

Skills Intelligence Takes Center Stage There's a fresh breeze blowing through the workforce planning domain, thanks to the newly expanded partnership between TalentNeuron and CodeSignal. They've strapped together their expertise to craft what's now touted as the most comprehensive skills intelligence available to organizations. A claim big enough to make us stop,...

Goodyear's Strategic Shift: New Leadership, New Path

Big Shoes, Bigger Expectations Who's steering the Goodyear ship now that Mark Stewart's out the door? Roger Wood's the name, interim CEO is the game. Don't fret too much—the board's hustling to nail down a permanent top dog. But this isn't a musical chairs game; it's a full-on strategic shift. Goodyear's forming committees, juggling ideas, and ripping through their...